Brainstorm Cell Therapeutics (BCLI) News Today $1.89 -0.10 (-5.03%) Closing price 01/17/2025 04:00 PM EasternExtended Trading$2.00 +0.11 (+5.82%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded at StockNews.comJanuary 21 at 1:49 AM | americanbankingnews.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Cut to "Sell" at StockNews.comJanuary 11, 2025 | americanbankingnews.comBCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS…January 6, 2025 | finance.yahoo.comBrainStorm Issues 2024 Letter to ShareholdersDecember 30, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate UpdateDecember 9, 2024 | prnewswire.comBrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform TechnologyDecember 3, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024December 2, 2024 | prnewswire.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 16, 2024 | finanznachrichten.deBrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 14, 2024 | prnewswire.comBrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial ManufacturingNovember 11, 2024 | prnewswire.comBrainStorm regains compliance with NasdaqOctober 31, 2024 | markets.businessinsider.comBrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 30, 2024 | prnewswire.comBrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS MeetingOctober 28, 2024 | prnewswire.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest UpdateBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI - Get Free Report) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 165,900 shares, an increase of 33.1% from the September 30th total of 124,600 shares. Approximately 3.4% of the shares of the company are short sold. Based on an average daily volume of 46,700 shares, the days-to-cover ratio is presently 3.6 days.October 27, 2024 | marketbeat.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200-Day Moving Average - Should You Sell?Brainstorm Cell Therapeutics (NASDAQ:BCLI) Share Price Passes Above 200 Day Moving Average - What's Next?October 18, 2024 | marketbeat.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Sees Large Decline in Short InterestBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI - Get Free Report) saw a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 124,600 shares, a decline of 91.1% from the September 15th total of 1,400,000 shares. Based on an average daily trading volume, of 35,000 shares, the short-interest ratio is currently 3.6 days. Currently, 2.6% of the company's shares are sold short.October 10, 2024 | marketbeat.comBrainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200 Day Moving Average - What's Next?Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Pass Above 200 Day Moving Average - Here's WhyOctober 9, 2024 | marketbeat.comBrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual SummitOctober 7, 2024 | prnewswire.comBrainstorm Cell (NASDAQ:BCLI) Stock, Short Interest ReportSeptember 28, 2024 | benzinga.comStrong Buy Recommendation for Brainstorm Cell Therapeutics Amid Positive Clinical Developments and Strategic FDA MilestonesSeptember 26, 2024 | markets.businessinsider.comBrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS MeetingSeptember 24, 2024 | prnewswire.comBrainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | seekingalpha.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | msn.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | finanznachrichten.deBrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | prnewswire.comBrainstorm Cell Therapeutics Inc (GHDN.DU)August 13, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics Q2 2024 Earnings PreviewAugust 13, 2024 | msn.comBrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate UpdateAugust 7, 2024 | prnewswire.comBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Insider Sells 63,000 SharesJuly 25, 2024 | insidertrades.comBCLI Update - Progress Supports Our 10x Plus Value Range PotentialJuly 24, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn ProgramJuly 1, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct OfferingJune 27, 2024 | prnewswire.comBrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical TrialJune 26, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating OfficerJune 20, 2024 | prnewswire.comBCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness ExpectationJune 14, 2024 | prnewswire.comBrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwnMay 20, 2024 | prnewswire.comBrainStorm Cell Therapeutics GAAP EPS of -$0.05 beats by $0.02May 16, 2024 | msn.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15, 2024 | finanznachrichten.deBrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | prnewswire.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwnApril 17, 2024 | finanznachrichten.deBrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical OfficerApril 17, 2024 | msn.comBrainstorm Cell Therapeutics (BCLI) Price Target Increased by 150.00% to 2.55April 17, 2024 | msn.comBrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical ChiefApril 17, 2024 | marketwatch.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value RuleApril 11, 2024 | finanznachrichten.deBCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…April 11, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value RuleApril 11, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALSApril 10, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALSApril 10, 2024 | prnewswire.comBrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALSApril 9, 2024 | finance.yahoo.comBrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALSApril 9, 2024 | prnewswire.com Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address BCLI Media Mentions By Week BCLI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCLI News Sentiment▼1.000.49▲Average Medical News Sentiment BCLI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCLI Articles This Week▼01▲BCLI Articles Average Week Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SCYX News Today ITRM News Today ELEV News Today RAPT News Today BRNS News Today CALC News Today ANEB News Today CASI News Today TPST News Today CLNN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCLI) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
